1. Positron increases production capacity due to increased demand. After the bell: Conceptus falls on lowered guidance
(Home Page/Home Page)

... into the next phase of development by Cempra," said Pedro Lichtinger, Optimer's President and CEO. Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products ...

2. LifeSci Advisors Initiates Coverage on Rockwell Medical
(News/Breaking News)

... (NASDAQ: RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease, and iron deficiency anemia. “Rockwell ...

3. BioMed News Bytes: Rockwell Medical, EXACT Sciences, MannKind
(Home Page/Home Page)

... treated achieved clinical responses defined as partial response (RECIST), change in PSA doubling time or stable disease for at least six months. On 10/29/09, RMTI announced the completion of its ...

4. RxNews Recap on Tuesday 10-27-09
(Home Page/Home Page)

... announced CEO Ron Wheet has been featured in the popular AllPennyStocks.com Spotlight series, produced by TheNewsWire.ca.   Rockwell Medical (NASDAQ:RMTI), a fully-integrated biopharmaceutical company ...

5. Coverage Initiated on Rockwell Medical (NASDAQ: RMTI)
(Home Page/Home Page)

Starting in 2005 and through late 2007 short sellers moderately shorted Rockwell Medical Technologies (NASDAQ: RMTI) which resulted in the stock price dropping from $9.39 to $4.33 by September 2007. ...

6. Rockwell Medical (NASDAQ: RMTI) Initiated at Outperform, $12 Target
(Home Page/Home Page)

On 10/12/09, Wedbush Morgan initiated coverage of Rockwell Medical (NASDAQ: RMTI) with an outperform rating and $12 per share fair value price target with a summary of the major points included below. ...

7. Surviving Wednesday's Wild Ride In Healthcare
(Home Page/Home Page)

...  SSRX 11.00 +0.51 (4.86%) 236.64M Losers (% price change) Rockwell Medical Tech RMTI 7.78 -1.22 (-13.56%) 110.54M Dyax Corp. DYAX 3.59 -0.48 (-11.79%) 260.17M ...

8. Rockwell Medical: Early-Stage AMAG Growth Potential
(Home Page/Home Page)

Rockwell Medical (NASDAQ:RMTI) has the potential for significant stock price gains by 2012 based on the enhanced earnings power of at least $4/share at that time for its lead clinical compound Soluble ...

9. Rockwell Medical: SFP is Key to Future Earnings Power
(Home Page/Home Page)

Rockwell Medical Technologies (NASDAQ:RMTI) is a small-cap bio-pharmaceutical company with a core, growing business which manufactures, sells, and distributes dialysate (which remove toxins and wastes ...

10. Rockwell Medical: SFP is Key to Future Earnings Power
(MyBlog/MyBlog)

Rockwell Medical Technologies (NASDAQ:RMTI) is a small-cap bio-pharmaceutical company with a core, growing business which manufactures, sells, and distributes dialysate (which remove toxins and wastes ...

11. FDA Calendar: 2H09 Binary Event Trades
(Home Page/Home Page)

... dependence. On 4/29/09, Rockwell Medical (NASDAQ:RMTI) announced the completion of patient enrollment in the Phase 2b study of SFP, which is a six-month, dose-ranging study in about 130 hemodialysis ...

12. FDA Calendar: 2H09 Binary Event Trades
(MyBlog/MyBlog)

... On 4/29/09, Rockwell Medical (NASDAQ:RMTI) announced the completion of patient enrollment in the Phase 2b study of SFP, which is a six-month, dose-ranging study in about 130 hemodialysis patients to determine ...

13. Big lineup of healthcare stocks crack Russell 3000® Index
(Home Page/Home Page)

... Poniard Pharmaceuticals, Inc.(NASDAQ:PARD) Repros Therapeutics Inc.(NASDAQ:RPRX) Rochester Medical Corporation(NASDAQ:ROCM) Rockwell Medical Technologies, Inc.(NASDAQ:RMTI) SciClone Pharmaceuticals, Inc.(NASDAQ:SCLN) ...

14. Russell's U.S. indexes move healthcare stocks - CXM, CTIC, HEB, and CPD
(Home Page/Home Page)

...  Change Mkt Cap Cardium Therapeutics Inc. CXM 2.90 +1.04 (55.91%) 136.10M Caraco Pharmaceutical CPD 3.39 +1.00 (41.84%) 126.98M Rockwell Medical Tech RMTI ...

15. 10 Extreme Trades on Pending Clinical Trial Results
(Home Page/Home Page)

... Company believes that overall survival data will be available from the SPEAR trial during 2H09. Rockwell Medical Technologies (NASDAQ:RMTI): RMTI is developing a water soluble iron replacement therapy ...

16. 10 Extreme Trades on Pending Clinical Trial Results
(MyBlog/MyBlog)

... available from the SPEAR trial during 2H09. Rockwell Medical Technologies (NASDAQ:RMTI): RMTI is developing a water soluble iron replacement therapy for dialysis patients called SFP for short (Soluble ...

17. BioMed Stock Updates: NASDAQ:RMTI, OTC:PRWP
(Home Page/Home Page)

Rockwell Medical (NASDAQ:RMTI) announced today that patient enrollment is completed for the Company's ongoing Phase 2b dose-ranging study for its iron replacement therapy soluble ferric pyrophosphate (SFP). ...

18. BioMed Stock Updates: RMTI, PRWP
(MyBlog/MyBlog)

Rockwell Medical (NASDAQ:RMTI) announced today that patient enrollment is completed for the Company's ongoing Phase 2b dose-ranging study for its iron replacement therapy soluble ferric pyrophosphate (SFP). ...

19. FDA, Clinical Trial Updates: NASDAQ:GTXI, NASDAQ:XNPT, NYSE:GSK, NASDAQ:RMTI
(Home Page/Home Page)

... leg syndrome (RLS). Rockwell Medical (NASDAQ:RMTI): In mid-April, RMTI announced that the independent Data Safety Monitoring Board (DSMB) providing oversight for the ongoing SFP Phase 2b dose-range study ...

20. FDA, Clinical Trial Updates: GTXI, GSK, XNPT, RMTI
(MyBlog/MyBlog)

... leg syndrome (RLS). Rockwell Medical (NASDAQ:RMTI): In mid-April, RMTI announced that the independent Data Safety Monitoring Board (DSMB) providing oversight for the ongoing SFP Phase 2b dose-range study ...

21. No Safety Concerns for RMTI's SFP Iron Treatment
(News/Latest News)

WIXOM, Mich., April 16, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (NasdaqGM:RMTI - News), a fully-integrated biopharmaceutical company offering innovative products and services targeting ...

22. No Safety Concerns for RMTI's SFP Iron Treatment
(MyBlog/MyBlog)

Rockwell Medical Technologies, Inc. (NasdaqGM:RMTI - News), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ERSD), chronic kidney ...

23. Rockwell Medical: Improving Margins, SFP Key to Future
(Home Page/Home Page)

In mid-March, Rockwell Medical Technologies (RMTI) reported 4Q and FY08 results which included revenue of $13.5M (up 13.3% from year-ago quarter) and $51.6M (up 20% compared to 2007). The net losses were ...

24. Rockwell Medical: Improving Margins, SFP Key to Future
(MyBlog/MyBlog)

In mid-March, Rockwell Medical Technologies (RMTI) reported 4Q and FY08 results which included revenue of $13.5M (up 13.3% from year-ago quarter) and $51.6M (up 20% compared to 2007). The net losses were ...

25. Rockwell Medical Presents New Data on Proprietary Iron-Delivery Drug SFP at American Society of Nephrology Annual Meeting
(News/Breaking News)

... -Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron-deficiency ...

26. Concateno Welcomes Funding Boost for Drug Treatment
(News/Breaking News)

Marketwire Blood-borne virus testing highlighted as good practice in reducing drug misuse WIXOM, MI--(Marketwire - November 2, 2009) -Rockwell Medical (ange name="NASDAQ">NASDAQ: RMTI), a fully-integrated ...

27. Asurion Mobile Applications Launches First Infinitely Expandable Socially Connected Address Book for Android-Based Phones
(News/Breaking News)

WIXOM, MI--Rockwell Medical (NASDAQ:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), ...

28. Rockwell Medical Announces New Corporate Name
(News/Breaking News)

Marketwire Company Unveils New Corporate Identity and Website WIXOM, MI--(Marketwire - October 27, 2009) -Rockwell Medical (NASDAQxchange>: RMTI), a fully-integrated biopharmaceutical company ...